A systematic review of the long-term health effects of in vitro fertilization (IVF) on women found that large cohort studies and clinical guidelines are generally reassuring: assisted reproductive technology (ART) has not been clearly linked to long-term increases in major cardiovascular events or breast cancer risk. However, complex questions remain about reproductive aging, specific cancer risks, and mental health.
The World Health Organization defines infertility as failure to achieve pregnancy after 12 months of regular unprotected sexual intercourse. It affects about 17.5% of adults. IVF, a core assisted reproductive treatment in which eggs are fertilized outside the body and embryos are transferred to the uterus, is widely used worldwide.
IVF usually involves controlled ovarian stimulation (COS), using exogenous gonadotropins to stimulate follicular development and GnRH agonists or antagonists to prevent premature ovulation. This produces estradiol levels above those of a natural cycle, prompting longstanding concerns about cardiovascular and cancer risks.
For cardiovascular safety, a meta-analysis of more than 500,000 women found that ART did not significantly increase the risk of cardiovascular events, stroke, coronary heart disease, hypertension, or diabetes over about 10 years of follow-up. Risk factors such as obesity and polycystic ovary syndrome (PCOS) are more common among women receiving IVF, but are themselves major determinants of cardiovascular disease, complicating causal assessment.
Long-term cancer data are also generally reassuring. In more than 20 years of follow-up, the OMEGA cohort found no higher breast cancer risk among women who underwent IVF than in the general population or other women with infertility. Guideline assessments generally find no increase in overall breast cancer risk, although caution is still advised with some medications, such as clomiphene used for more than 10 cycles.
Some studies have observed a small increase in borderline ovarian tumors among people receiving fertility treatment, but it remains difficult to distinguish an effect of treatment from underlying infertility factors such as endometriosis and nulliparity. Overall, no significant increase in endometrial cancer risk has been found.
Reproductive aging is assessed mainly through markers of ovarian reserve such as anti-Müllerian hormone (AMH) and antral follicle count (AFC). Recent data suggest that AMH below 1.1 ng/mL is associated with fewer retrieved eggs and a higher risk of cycle cancellation, but does not necessarily indicate poorer egg quality in younger patients. Once a transferable embryo is obtained, pregnancy outcomes are similar to those of women with normal ovarian reserve.
Evidence on the timing of menopause remains limited. One cross-sectional study found a mean menopausal age of 49.8 years in women who had IVF and 50.7 years in controls, a difference of about 10 months. Although statistically significant, researchers considered the clinical significance limited and said it may reflect underlying reproductive differences rather than a direct effect of IVF.
Hormonal exposure and physiological stress during IVF have also drawn attention. Ovarian hyperstimulation syndrome (OHSS) remains an important short-term complication and may involve fluid shifts, altered vascular permeability, and thrombosis risk. Over the long term, inflammation may be related to ovarian response and reproductive capacity, but clear causal evidence is lacking.
The uncertainty and financial pressure of IVF may create a substantial psychological burden. Long-term follow-up shows that women who do not have a child are more likely to experience depression and anxiety, while the mental health of those who give birth is generally stable. Psychological support should therefore be an important part of fertility care.
A central challenge in current evidence is confounding: women receiving IVF often already have endocrine abnormalities, ovulatory disorders, or nulliparity, which are themselves associated with long-term health risks. Separating treatment effects from underlying risk is therefore difficult.
Most available data come from observational studies with limited follow-up, particularly for late-onset conditions such as some cancers. Future research should stratify by treatment protocol, number of cycles, and underlying disease to produce more precise conclusions.
As assisted reproductive technology advances, evaluation is shifting from whether it is safe to which patients and circumstances are safest, marking a move toward more precise management in reproductive medicine.
News | Long-term effects of IVF on women's health
News | Long-term effects of IVF on women's health
A systematic review of the long-term health effects of in vitro fertilization (IVF) on women found that large cohort studies and clinical guidelines are generally reassuring: assisted reproductive technology (ART) has not been clearly linked to long-term increases in major cardiovascular events or breast cancer risk. However, complex questions remain about reproductive aging, specific cancer risks, and mental health.
The World Health Organization defines infertility as failure to achieve pregnancy after 12 months of regular unprotected sexual intercourse. It affects about 17.5% of adults. IVF, a core assisted reproductive treatment in which eggs are fertilized outside the body and embryos are transferred to the uterus, is widely used worldwide.
IVF usually involves controlled ovarian stimulation (COS), using exogenous gonadotropins to stimulate follicular development and GnRH agonists or antagonists to prevent premature ovulation. This produces estradiol levels above those of a natural cycle, prompting longstanding concerns about cardiovascular and cancer risks.
For cardiovascular safety, a meta-analysis of more than 500,000 women found that ART did not significantly increase the risk of cardiovascular events, stroke, coronary heart disease, hypertension, or diabetes over about 10 years of follow-up. Risk factors such as obesity and polycystic ovary syndrome (PCOS) are more common among women receiving IVF, but are themselves major determinants of cardiovascular disease, complicating causal assessment.
Long-term cancer data are also generally reassuring. In more than 20 years of follow-up, the OMEGA cohort found no higher breast cancer risk among women who underwent IVF than in the general population or other women with infertility. Guideline assessments generally find no increase in overall breast cancer risk, although caution is still advised with some medications, such as clomiphene used for more than 10 cycles.
Some studies have observed a small increase in borderline ovarian tumors among people receiving fertility treatment, but it remains difficult to distinguish an effect of treatment from underlying infertility factors such as endometriosis and nulliparity. Overall, no significant increase in endometrial cancer risk has been found.
Reproductive aging is assessed mainly through markers of ovarian reserve such as anti-Müllerian hormone (AMH) and antral follicle count (AFC). Recent data suggest that AMH below 1.1 ng/mL is associated with fewer retrieved eggs and a higher risk of cycle cancellation, but does not necessarily indicate poorer egg quality in younger patients. Once a transferable embryo is obtained, pregnancy outcomes are similar to those of women with normal ovarian reserve.
Evidence on the timing of menopause remains limited. One cross-sectional study found a mean menopausal age of 49.8 years in women who had IVF and 50.7 years in controls, a difference of about 10 months. Although statistically significant, researchers considered the clinical significance limited and said it may reflect underlying reproductive differences rather than a direct effect of IVF.
Hormonal exposure and physiological stress during IVF have also drawn attention. Ovarian hyperstimulation syndrome (OHSS) remains an important short-term complication and may involve fluid shifts, altered vascular permeability, and thrombosis risk. Over the long term, inflammation may be related to ovarian response and reproductive capacity, but clear causal evidence is lacking.
The uncertainty and financial pressure of IVF may create a substantial psychological burden. Long-term follow-up shows that women who do not have a child are more likely to experience depression and anxiety, while the mental health of those who give birth is generally stable. Psychological support should therefore be an important part of fertility care.
A central challenge in current evidence is confounding: women receiving IVF often already have endocrine abnormalities, ovulatory disorders, or nulliparity, which are themselves associated with long-term health risks. Separating treatment effects from underlying risk is therefore difficult.
Most available data come from observational studies with limited follow-up, particularly for late-onset conditions such as some cancers. Future research should stratify by treatment protocol, number of cycles, and underlying disease to produce more precise conclusions.
As assisted reproductive technology advances, evaluation is shifting from whether it is safe to which patients and circumstances are safest, marking a move toward more precise management in reproductive medicine.
Source:
Compiled from online sources